Employing a mouse model of IDH-mutant glioma, the authors demonstrated that selective inhibition of mutant IDH suppresses 2-HG production, restoring T-cell immunity and enhancing the anti-tumor effect of immune checkpoint inhibitor. Here, IDH1 is linked to glioma.